Shell Says It's Not in Talks to Buy BP
Bloomberg Markets
TV Shows
Shell Plc denied a Wall Street Journal report that it is in active talks about acquiring its London-based oil rival BP Plc. 'This is further market speculation. No talks are taking place,' a Shell spokesperson said. Bloomberg's Simon Casey reports. (Source: Bloomberg)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Worldline shares regain some ground after Wednesday's 38% fall
(Reuters) -Worldline shares recovered some of their losses in early trade on Thursday, after allegations by a media consortium sent the payments group's stock falling by 38% on Wednesday, wiping out 500 million euros ($585 million) of its market value. A group of 21 European media outlets on Wednesday alleged Worldline continued doing business with merchants that German regulator BaFin had banned its German subsidiary Payone from working with in 2023 for failing to comply with anti-money laundering and anti-fraud requirements. In response to the reports, the French company said that, since 2023, it had strengthened merchant risk controls and terminated non-compliant client relationships. ($1 = 0.8549 euros) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Canaccord Genuity Maintains a Buy on Inventiva (IVA) With a $20 Price Target
Inventiva S.A. (NASDAQ:IVA) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Inventiva S.A. (NASDAQ:IVA) on June 5, keeping the price target at $20.00. The rating was based on several factors, including the potential of lanifibranor, the company's lead asset in the MASH space. Lanifibranor's oral administration and direct anti-fibrotic effects distinguish it from other treatments in development, with a primary focus on liver fat reduction. A research scientist in an idiopathic pulmonary fibrosis laboratory, carrying out clinical trials. The analyst also reasoned that Lanifibranor can be used in conjunction with other treatments, including GLP-1s and SGLT2 inhibitors. This factor is a significant boost to its appeal, especially when considering the high prevalence of type 2 diabetes in MASH patients. Nash stated that the drug is progressing well, which can be corroborated by the completion of full enrollment in the Phase III NATiV3 trial and the anticipated top-line data in H2 2026. Major pharmaceutical companies are also showing increasing interest in the MASH space, further supporting the optimistic outlook for Inventiva S.A. (NASDAQ:IVA). Inventiva S.A. (NASDAQ:IVA) is a clinical-stage biopharmaceutical company that develops oral small-molecule therapies to treat non-alcoholic steatohepatitis or NASH. It also develops therapies for other diseases with considerable unmet medical needs. While we acknowledge the potential of IVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Bloomberg
29 minutes ago
- Bloomberg
Starmer in Talks With Labour Rebels About Easing Welfare Cuts
Prime Minister Keir Starmer looks ready to water down another of the UK government's key policies, offering concessions to stop Labour party colleagues derailing his reforms to Britain's expensive welfare payments. Starmer's government planned to save £5 billion ($6.9 billion) a year by tightening criteria for disability payments, yet this week over 100 of Labour's own Members of Parliament put their names to an amendment that could effectively kill the new laws at a vote next Tuesday.
